AtriCure, Inc.
ATRC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.73 | 1.54 | 0.23 | -0.32 |
| FCF Yield | -0.78% | -2.27% | -1.92% | -0.75% |
| EV / EBITDA | -74.95 | -202.61 | -69.36 | -85.89 |
| Quality | ||||
| ROIC | -7.60% | -5.02% | -8.06% | 9.78% |
| Gross Margin | 74.69% | 75.23% | 74.44% | 75.04% |
| Cash Conversion Ratio | – | -0.15 | 0.48 | -0.27 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.09% | 13.32% | 16.95% | 5.93% |
| Free Cash Flow Growth | 70.00% | 3.86% | -65.82% | 6.35% |
| Safety | ||||
| Net Debt / EBITDA | 2.49 | 1.21 | -0.56 | -0.87 |
| Interest Coverage | -6.25 | -3.85 | -8.56 | 11.23 |
| Efficiency | ||||
| Inventory Turnover | 1.56 | 1.46 | 1.84 | 1.76 |
| Cash Conversion Cycle | 203.22 | 197.66 | 159.70 | 152.51 |